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IMPACT OF DEXMEDETOMIDINE ON OPIOID AND 
BENZODIAZEPINE DOSING REQUIREMENTS IN CHILDREN
Amy E. Helvie*, PharmD, Chad A. Knoderer, PharmD, Iftekhar D. Kalsekar, PhD, 
Brandon T. Kibby, DO, Michael S. Mazurek, MD
*Department of Pharmacy, Riley Hospital for Children, Indianapolis IN.
BACKGROUND
 Dexmedetomidine is a potent and selective alpha2-adrenergic agonist which
has sedative, analgesic, and anxiolytic effects.  
 In adults, dexmedetomidine has been shown to decrease opioid dosing 
requirements when utilized for pain and sedation management.  
 We hypothesized that similar to adult data, the addition of dexmedetomidine to 
standard pain and sedation management protocols may reduce the overall opioid 
and benzodiazepine dosing requirements in children after cardiac surgery.
OBJECTIVES
To determine the difference in opioid and benzodiazepine dosing
requirements in children treated with and without dexmedetomidine after
cardiac surgery.
METHODS
Study Design
IRB approved retrospective cohort study
Data Source
 Computer generated lists were used to randomly select both case (DEX) and 
comparison (COMP) subjects.
 Dosing information was collected via medication administration records for the 
duration of anesthesiologist management.
Patient Population
 Patients included were pediatric cardiovascular surgery patients who were admitted 
to the intensive care unit post-operatively.
 Exclusion criteria:
Patients greater than 18 years
Cardiovascular surgery patients whose operative procedure was not performed 
for repair or palliation of a congenital heart defect 
Dexmedetomidine patients who did not have dexmedetomidine initiated within 24 
hours of surgery.
Pain and Sedation Management
 Standard pain management and sedation protocol managed by pediatric 
anesthesiologist in all patients.
 Therapeutic options and dosing were dependent on patient’s airway status.
Mechanically ventilated
Continuous fentanyl infusion
As needed (PRN) IV morphine
PRN IV midazolam
+/- dexmedetomidine 
Spontaneously breathing
PRN IV morphine
PRN IV midazolam
+/- dexmedetomidine 
Data Analysis
 Total cumulative doses of fentanyl, morphine, and midazolam were determined.
 For equal comparison, opioid dosing was standardized by using equipotent 
morphine doses.
. 
RESULTS
Thirty six patients in each group were included.
Baseline Demographics 
•No difference between groups
Continuous Infusions
Fentanyl
Administered to 18 (50%) in the DEX group and 14 (38%) in the COMP group
DEX group required fewer days of therapy 4.8 vs. 8.9 (p = 0.064)
Midazolam
Not utilized in any patient
Dexmedetomidine
Mean initial infusion:  0.34 ± 0.1 mcg/kg/hr
Maximum infusion: 0.44 ± 0.17 mcg/kg/hr
Bolus doses administered to 8 patients (22%)
Average length of infusion:  2.4 ± 1.9 days
DISCUSSION
When compared to a historical control population, dexmedetomidine administration 
to children within 24 hours after surgery for congenital heart disease, was associated 
with a 37% reduction in total daily opioid dosing requirement, although not 
statistically significant.
Decreased opioid use may also result in decreased PICU days and 
decreased incidences of opioid withdrawal, both of which impact overall 
length of stay and associated healthcare costs. 
Trending towards statistical significance, a reduction in continuous fentanyl 
infusion requirements was also observed.
In our study, cumulative midazolam dosing requirements were higher in patients 
who received dexmedetomidine, although not statistically significant.  
This could be explained by limited upward dexmedetomidine dose titration 
and may signify that the dexmedetomidine doses were not optimized to 
achieve desired sedation outcomes.
Baseline Demographics
Dexmedetomidine
(n = 36)
No 
Dexmedetomidine
(n = 36)
p
Age* 
(months)
50.9 (0.85 – 207.4) 44.9 (0.13 – 233) 0.707
Weight* 
(kg)
18.5 (3.2 – 104) 16.4 (2 – 99)                   0.695
Male 21 (58%) 20 (56%) 0.812
Bypass 35 (97%) 34 (94%) 0.555
Intubated 26 (72%) 20 (56%) 0.141
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RESULTS
Opioid and Midazolam Dosing Requirements
 Total daily opioid dosing requirements were reduced 37% in the dexmedetomidine 
verus the comparison group.
 Patients in the dexmedetomidine group had higher midazolam dosing requirements.
p = 0.44 p = 0.071
p = 0.78 p = 0.21
